BriaCell Therapeutics Financials

BCTXW Stock  USD 0.10  0.01  9.09%   
Based on the key indicators related to BriaCell Therapeutics' liquidity, profitability, solvency, and operating efficiency, BriaCell Therapeutics Corp may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, BriaCell Therapeutics' Other Current Assets are fairly stable compared to the past year. Key indicators impacting BriaCell Therapeutics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio0.420.44
Sufficiently Down
Pretty Stable
Investors should never underestimate BriaCell Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor BriaCell Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in BriaCell Therapeutics Corp.

Net Income

(4.1 Million)

  
Understanding current and past BriaCell Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BriaCell Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in BriaCell Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in BriaCell Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BriaCell Therapeutics Corp. Check BriaCell Therapeutics' Beneish M Score to see the likelihood of BriaCell Therapeutics' management manipulating its earnings.

BriaCell Therapeutics Stock Summary

BriaCell Therapeutics competes with Briacell Therapeutics, and Reviva Pharmaceuticals. BriaCell Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIP10778Y112
LocationBritish Columbia; Canada
Business AddressBellevue Centre, West
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitebriacell.com
Phone604 921 1810
CurrencyUSD - US Dollar

BriaCell Therapeutics Key Financial Ratios

BriaCell Therapeutics Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets58.0M42.6M27.2M5.9M6.8M10.3M
Net Debt(57.2M)(41.0M)(21.3M)(862.1K)(775.9K)(814.7K)
Retained Earnings(15.8M)(60.3M)(80.7M)(85.4M)(76.9M)(73.1M)
Accounts Payable214.1K463.3K1.1M7.2M8.2M8.7M
Cash57.3M41.0M21.3M862.1K991.4K941.8K
Total Liab782.2K32.2M30.9M8.6M9.8M10.3M
Total Current Assets57.8M42.3M26.9M3.7M4.2M4.0M
Net Receivables12.6K24.1K717.7K1.4M1.6M1.7M
Other Current Liab342.7K477.8K677.7K290.4K333.9K657.3K
Inventory1.0(24.1K)(18.9K)(1.4M)(1.2M)(1.2M)
Other Current Assets516.9K1.3M5.0M1.4M1.6M1.7M
Intangible Assets245.6K230.3K215.1K199.8K229.8K182.9K
Net Invested Capital57.3M10.3M(3.8M)(2.4M)(2.7M)(2.6M)
Net Working Capital57.2M41.4M25.1M(3.8M)(4.4M)(4.2M)
Capital Stock54.8M65.6M69.6M72.2M83.0M45.8M
Common Stock54.8M65.6M69.6M72.2M83.0M45.8M

BriaCell Therapeutics Key Income Statement Accounts

The reason investors look at the income statement is to determine what BriaCell Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
202020212022202320242025 (projected)
Operating Income(7.0M)(15.3M)(23.3M)(4.8M)(4.3M)(4.5M)
Ebit1.4M3.7M(11.5M)(22.4M)(20.1M)(19.1M)
Ebitda3.7M(11.5M)(22.4M)(4.8M)(4.3M)(4.1M)
Income Before Tax3.7M(11.5M)(20.3M)(4.8M)(4.3M)(4.1M)
Net Income3.7M(11.5M)(20.3M)(4.8M)(4.3M)(4.1M)
Income Tax Expense(72.3K)6.6M979.0(152.6K)(175.5K)(166.7K)
Research Development1.3M8.0M15.3M27.2M31.3M32.8M
Interest Income3.1K136.7K891.2K288.0K331.2K177.7K
Net Interest Income(42.9K)(11.5M)891.2K288.0K259.2K272.2K
Gross Profit(14.0K)(15.6K)(15.1K)(15.5K)(14.0K)(14.7K)
Cost Of Revenue14.0K15.6K15.1K15.5K17.9K16.4K

BriaCell Therapeutics Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash57.2M(16.2M)(19.8M)(20.4M)(18.4M)(17.4M)
Free Cash Flow(7.7M)(12.5M)(23.7M)(24.6M)(22.1M)(21.0M)
Net Income(428.3K)(26.8M)(20.3M)(4.9M)(4.4M)(4.7M)
End Period Cash Flow57.3M41.0M21.3M862.1K991.4K941.8K
Other Non Cash Items1.8M(2.4K)(1.1M)(21.1M)(19.0M)(18.0M)
Depreciation15.3K15.3K15.3K83.9K96.5K101.3K

BriaCell Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining BriaCell Therapeutics's current stock value. Our valuation model uses many indicators to compare BriaCell Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BriaCell Therapeutics competition to find correlations between indicators driving BriaCell Therapeutics's intrinsic value. More Info.
BriaCell Therapeutics Corp is rated fifth in return on equity category among its peers. It also is rated fifth in return on asset category among its peers . At this time, BriaCell Therapeutics' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value BriaCell Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

BriaCell Therapeutics Systematic Risk

BriaCell Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BriaCell Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on BriaCell Therapeutics correlated with the market. If Beta is less than 0 BriaCell Therapeutics generally moves in the opposite direction as compared to the market. If BriaCell Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BriaCell Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BriaCell Therapeutics is generally in the same direction as the market. If Beta > 1 BriaCell Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in BriaCell Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BriaCell Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of BriaCell Therapeutics growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.63)

At this time, BriaCell Therapeutics' Price Earnings To Growth Ratio is fairly stable compared to the past year.

BriaCell Therapeutics March 2, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of BriaCell Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BriaCell Therapeutics Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of BriaCell Therapeutics Corp based on widely used predictive technical indicators. In general, we focus on analyzing BriaCell Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BriaCell Therapeutics's daily price indicators and compare them against related drivers.

Additional Tools for BriaCell Stock Analysis

When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.